A defining moment for RAS medicine: Daraxonrasib delivers historic Phase 3 results in pancreatic cancer

The RAS Dialogue Blog posts are written by RAS experts sharing the latest research, updates, and scientific RAS news. The content is curated by the RAS Initiative.

For decades, the RAS field has been driven by a simple but extraordinarily difficult goal: Translate our growing understanding of RAS biology into meaningful benefits for patients.

This month, that goal came substantially closer to reality.

The Phase 3 RASolute 302 study reported that daraxonrasib, a RAS(ON) multiselective inhibitor developed by Revolution Medicines, significantly improved survival in previously treated metastatic pancreatic ductal adenocarcinoma (mPDAC), one of the deadliest malignancies in medicine. 

Median overall survival increased from 6.6 months with physician's-choice chemotherapy to 13.2 months with daraxonrasib, corresponding to a remarkable 60% reduction in the risk of death (hazard ratio 0.40). Progression-free survival also improved substantially, from 3.5 months to 7.3 months.

These are not incremental gains. They represent one of the largest survival improvements ever reported in a randomized pancreatic cancer trial.

More importantly, they may signal the beginning of a new era for RAS-directed therapy.

Mark A. Goldsmith, M.D., Ph.D., chief executive officer and chairman of Revolution Medicines, said the broad potential of RAS(ON) inhibition is validated by the data from the Phase 3 RASolute 302 trial.

He said daraxonrasib has achieved striking results by reducing the risk of death by 60% and increasing median overall survival to more than one year in previously treated metastatic pancreatic cancer, a result not previously reported in any Phase 3 clinical trial in any line of therapy for this disease.

“This firmly supports our science-driven approach to developing bold, new targeted medicines for treating patients with RAS-driven cancers,” Goldsmith said. “These results usher in a new era of RAS-targeted therapy, significantly elevate the survival bar in the treatment of one of the deadliest human cancers, and redefine treatment expectations while better preserving quality of life compared to chemotherapy.”

He said they are focused on this broad potential and are testing across pancreatic cancer and other RAS-driven cancers.

Why the results are so significant

Pancreatic ductal adenocarcinoma has long been considered one of the most RAS-dependent cancers. More than 90% of PDAC tumors harbor oncogenic RAS mutations, with the overwhelming majority involving KRAS codon 12 alterations. 

Yet despite decades of research establishing RAS as the central driver of pancreatic tumor biology, therapeutic exploitation of this vulnerability has remained frustratingly elusive. 

The emergence of allele-specific KRAS inhibitors transformed the treatment landscape for certain subsets of lung cancer driven by KRAS G12C. However, pancreatic cancer presents a more challenging molecular landscape. KRAS G12D predominates, and tumors frequently develop adaptive resistance mechanisms.

Daraxonrasib was designed to address this challenge through a fundamentally different strategy. Rather than targeting a single mutant allele, the drug is a RAS(ON) multiselective tri-complex inhibitor that engages the active, GTP-bound form of RAS. 

Daraxonrasib inhibits mutant and wild-type forms of KRAS, NRAS and HRAS across multiple clinically relevant mutations, including G12, G13 and Q61 variants. 

The RASolute 302 results, therefore, represent more than a successful pancreatic cancer trial. They provide the strongest clinical validation to date for direct inhibition of active-state RAS signaling as a therapeutic strategy.

Image

The numbers that matter

Among the 500 patients enrolled, approximately 92% had tumors harboring RAS G12 mutations. Patients were randomized to receive either once-daily oral daraxonrasib or investigator's choice chemotherapy. 

Key findings included:

• Median overall survival: 13.2 months vs. 6.6 months (hazard ratio 0.40) 
• Median progression-free survival: 7.3 months vs. 3.5 months (hazard ratio 0.45) 
• Objective response rate: 33.2% vs. 11.8% 
• Significant delays in time to deterioration measured by pain and global health status
• Lower treatment discontinuation rates despite longer treatment duration 

Perhaps most striking is the magnitude of the survival benefit.

The trial was powered assuming a hazard ratio of 0.70 for overall survival. Instead, investigators observed a hazard ratio of 0.40, substantially exceeding expectations. 

Such a result is rare in contemporary oncology and especially noteworthy in metastatic pancreatic cancer, where therapeutic advances have historically been measured in weeks rather than months.

Image

Validation of a long-held hypothesis

From a scientific perspective, the trial offers powerful support for a concept that has guided much of RAS research over the past decade.

The field has increasingly recognized that sustained suppression of active RAS signaling may be required to achieve meaningful clinical benefit in RAS-driven tumors. While preclinical evidence for this hypothesis has accumulated steadily, definitive clinical validation has remained limited.

RASolute 302 changes that conversation.

The study demonstrates that broad inhibition of active-state RAS can translate into substantial improvements in survival, disease control, and patient-reported outcomes in a cancer where RAS signaling is the dominant oncogenic driver. 

For many investigators, this may represent the strongest evidence yet that RAS addiction can be therapeutically exploited at scale.

Questions that come next

As transformative as these results appear, they also raise important questions:

• Can similar benefits be achieved in the first-line setting?
• Will combinations with immunotherapy, SHP2 inhibitors or other pathway-targeted agents produce even deeper responses?
• How broadly will active-state RAS inhibition translate across other RAS-driven malignancies?
• And perhaps most importantly, what mechanisms of resistance will emerge after prolonged RAS(ON) suppression?

The answers to these questions will likely shape the next decade of RAS research.

Looking back and looking forward

For many years, RAS was considered one of oncology's most formidable targets. The field has since witnessed a remarkable evolution from structural biology breakthroughs and allele-specific inhibitors to increasingly sophisticated approaches targeting the active state of RAS signaling. 

The RASolute 302 results are another pivotal milestone in that journey.

Whether daraxonrasib becomes the new standard of care in previously treated metastatic pancreatic cancer will be determined by regulators and clinicians. But the broader significance is already clear.

This trial provides compelling evidence that direct RAS inhibition can translate into meaningful clinical benefit in one of the most RAS-driven human malignancies. 

Beyond its implications for pancreatic cancer, the study represents an important validation of the therapeutic strategy of targeting active-state RAS signaling and is likely to influence the direction of both clinical development and translational research across the field.

Generative AI tools were used to assist with drafting and editing portions of this article. All content was reviewed, fact-checked, and edited by the author.

If you're interested in participating in the dialogue, consider joining RASLab. RAS Lab is an online discussion forum to facilitate the exchange of scientific information among researchers in cancers related to RAS. If you would like to join RAS Lab, send an email to SolveRAS@nih.gov with the subject line "I would like to join RAS Lab."